Trials / Active Not Recruiting
Active Not RecruitingNCT04331119
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Phase II Trial With Safety Lead in of Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant in patients with T-cell lymphomas will be safe and well tolerated, and will improve progression free survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Duvelisib | SecuraBio will supply duvelisib |
| PROCEDURE | Peripheral blood draw | -Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies |
Timeline
- Start date
- 2020-07-23
- Primary completion
- 2026-04-22
- Completion
- 2026-04-22
- First posted
- 2020-04-02
- Last updated
- 2025-12-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04331119. Inclusion in this directory is not an endorsement.